<DOC>
	<DOCNO>NCT03033498</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics single , ascend dos ABBV-951 administer subcutaneous infusion subject Parkinson 's disease .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Subcutaneous Infusions ABBV-951 Subjects With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subject diagnosis definite idiopathic PD , LD responsive , accord United Kingdom Parkinson 's Disease Society Brain Bank Criteria . Subject must take optimized stable regimen oral medication PD , remain stable unchanged least 30 day dose study . This regimen must include oral carbidopa/levodopa ( CD/LD ) immediate release and/or CD/LD control release tablet ( e.g. , Sinemet Sinemet CR ) , also must stable dose least 30 day dose . Subject must receive least three daily dos LD . Females must negative result pregnancy test screen prior confinement . If male , subject must surgically sterile practice adequate method birth control initial study drug administration 90 day last dose study drug . Body Mass Index ( BMI ) 18.0 35.0 , inclusive . A condition general good health , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram ( ECG ) . Receipt drug injection within 30 day within period define 5 halflives , whichever longer , prior study drug administration . History significant skin condition disorder ( e.g. , psoriasis , atopic dermatitis , etc . ) evidence recent sunburn , acne , scar tissue , tattoo , open wound , branding , coloration Investigator 's opinion would interfere infusion study drug could interfere study assessment . Use medication prohibit concomitant therapy . Positive screen drug abuse , alcohol , cotinine . Subjects glomerular filtration ratio ( GFR ) less 45 ml/min/1.73 m2 determine Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) creatinine equation . Donation loss 550 mL blood volume ( include plasmapheresis ) receipt transfusion blood product within 8 week prior initial study drug administration . Consideration investigator reason subject unsuitable candidate receive ABBV951 .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>